Formyl peptide receptor (FPR)-desensitized neutrophils display increased production/release of superoxide (O 2 2 ) when activated by platelet-activating factor (PAF), a priming of the response achieved through a unique receptor crosstalk mechanism. The aim of this study was to determine the effect of an inhibitor selective for small, heterotrimeric G proteins belonging to the Gaq subclass on that receptor crosstalk. We show that signals generated by FPRs and the PAF receptor (PAFR) induce activation of the neutrophil O 2 2 , producing NADPHoxidase, and that response was sensitive to Gaq inhibition in cells activated by PAF, but no inhibition was obtained in cells activated by FPR agonists. Signaling in naive neutrophils is terminated fairly rapidly, and the receptors become homologously desensitized. The downstream sensitivity to Gaq inhibition in desensitized cells displaying increased production/release of O 2 2 through the PAFR receptor crosstalk mechanism also comprised the reactivation of the FPRs, and the activation signals were redirected from the PAFR to the desensitized/reactivated FPRs. The Gaq-dependent activation signals generated by the PAFRs activate the Gaicoupled FPRs, a receptor crosstalk that represents a novel pathway by which G protein-coupled receptors can be regulated and signaling can be turned on and off.
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Introduction
Neutrophils, professional phagocytes of our first line of defense against bacterial invaders and regulators of inflammation, express many different GPCRs [1, 2] . The signaling scheme for how cellular responses are triggered by these receptors [1, 3] is in agreement with the generally accepted signaling paradigm for other mammalian GPCRs [4] . The starting point in this scheme is agonist binding to receptor domains exposed on the plasma membrane of the receptor-expressing cell, and the occupied receptors are then stabilized in an active signaling conformation that transfers the primary signal to the G protein-binding structures exposed on the cytosolic domains of the receptor. This conformational change induces receptor-driven dissociation of the heterotrimeric G protein complexes into actively signaling a and bg subunits, respectively [5] . The G protein signaling is subsequently terminated, and the occupied receptor becomes refractory to further stimulation with the same agonist and to other agonists that bind the same receptor, an effect commonly termed homologous receptor desensitization, and the process is needed to avoid continued receptor signaling deleterious to cells and/or tissues. The precise mechanisms that regulate desensitization of GPCRs in neutrophils is not known in detail, but the actin cytoskeleton, and not b-arrestin [6] , may be part of the regulatory machinery for desensitization [7] . In neutrophils there is a defined receptor hierarchy, illustrated by cells activated by one receptor-specific agonist gradually becoming nonresponsive to further stimulation, not only to agonists that employ the same receptor but also to ligands that bind other unrelated receptors, a type of receptor crosstalk known as heterologous desensitization [8, 9] . No cross-desensitization is observed when two receptors are equally strong hierarchically [10] , and activation of a lower-ranked receptor may actually prime the response induced by a higher-ranked receptor. Irrespective of the precise mechanism leading to receptor desensitization, this state was long thought to be a point at which no further G protein signaling was allowed. We have, however, recently shown that FPRs desensitized with receptor-specific agonists can be reactivated by a crosstalk mechanism involving PAFR and ATP (P2Y 2 R) being occupied by their respective agonist [11, 12] . The mechanisms that underlie receptor desensitization and the novel receptor crosstalk mechanism for amplification of the neutrophil response is not known but might involve a signal downstream of the activating receptor that affects the desensitized receptor and induces/allows its reactivation. Despite this, it is clear that neutrophil function relies on a number of complex processes that are dependent on multiple receptor-ligand interactions, which initiate phenotypic changes, for example, during extravasation, neutrophil states characterized by hypo-as well as hyperresponsiveness to subsequent stimulation [13] . It is well established that neutrophil activation through GPCRs, after a period of signaling, are terminated, and the occupied receptor becomes desensitized, and this mechanism functions to limit recruitment and/or to reduce the effects of potentially harmful effector functions. It is also clear that the desensitized receptor state, constitutes the basis for priming of the response when desensitized neutrophils are reactivated by agonist specific for other GPCRs [11, 12] . Based on sequence homologies, the four main subfamilies of heterotrimeric G proteins contain different a subunits (Gai/Go, Gaq, Gas, Ga 12/13 ) that, when activated by the agonist-occupied receptor, transduce different downstream signals. It may, however, be hard to conclusively identify the precise G protein(s) responsible for signaling. Even if bacterial toxins have been valuable tools in defining involvement of Gai (sensitive to the classic Bordetella pertussis toxin) and Gas (sensitive to the classic Vibrio cholera toxin) in the downstream signaling of different receptors [14] , additional inhibitors with specificity for the different G protein subunits have been eagerly awaited to properly determine the use of the various Ga subtypes. The involvement of yet another Ga subtype can now be defined because two membrane-permeable, cyclic depsipeptides, produced by growing Chromobacterium sp. QS3666 (YM-254890) and the plant Ardisia crenata (FR900359), respectively, are now available [15, 16] . Both these depsipeptides have been shown to selectively inhibit signal transduction mediated through Gaq because they rapidly and selectively inhibit the exchange of GDP for GTP upon receptor activation of Gaq-containing G proteins, and signaling downstream of this G protein is thus inhibited [17] . We have used these Gaq-selective inhibitors to characterize the response induced in neutrophils by agonists for FPRs and for the PAFR, receptors earlier shown to be partners in a novel crosstalk-signaling pathway, leading to a reactivation of desensitized FPRs [11, 12, 18] .
The cellular responses in neutrophils activated with a PAFRspecific agonist, as well as with an FPR2-specific agonist, include the PLC-PIP 2 -IP 3 pathway leading to an emptying of intracellular Ca 2+ stores and a concomitant rise in the cytosolic concentration of free Ca 2+ , as well as to a direct activation of the O 2 2 -generating NADPH oxidase. We show that the signals generated were unaffected by Gaq inhibition when these responses were triggered by an FPR2 agonist, whereas the responses generated by PAF were inhibited. This knowledge was used to characterize the novel receptor crosstalk between the PAFRs and the FPRs, using neutrophils and monocytes desensitized with FPR agonists. 
MATERIALS AND METHODS

Ethics statement
This study, conducted at Sahlgrenska Academy in Sweden, includes blood from buffy coats obtained from the blood bank at the component laboratory at Sahlgrenska University Hospital (Gothenburg, Sweden). Ethics approval was not needed because the buffy coats were provided anonymously and could not be traced back to a specific individual. This is in line with Swedish legislation section code 4 § 3p SFS 2003:460 (Lag om etikprövning av forskning som avser människor).
Chemicals
Dextran and Ficoll-Paque were obtained from GE Healthcare Life Sciences (Uppsala, Sweden). HRP was obtained from Sigma-Aldrich Chemie (Steinheim, Germany). The PIP 2 -binding peptide PBP 10 (for details about this inhibitory molecule, see Forsman et al. [19] ), the pepducin F2Pal 10 [20] , and the PSMa2 1-16 peptide [21] were synthesized and HPLC-purified by CASLO Laboratory (Lyngby, Denmark). The pepducin was synthesized by Fmoc solidphase peptide synthesis, and N-terminal palmitoylation was made on the resin as the last step before deprotection of side chains. PBP 10 peptide (RhB-QRLFQVKGRR), the formylated peptide fMIFL, and the FPR2 antagonist WRWWWW were also obtained from CASLO Laboratory, whereas cyclosporin H was kindly provided by Novartis Pharmaceuticals (Basel, Switzerland). The hexapeptide WKYMVM was purchased from Alta Bioscience (University of Birmingham, Birmingham, United Kingdom). PMA was purchased from SigmaAldrich, whereas PAF was from Avanti Polar Lipids (Alabaster, AL, USA). The FPR2-specific, lipidated a-peptide/b-peptoid Pam-(Lys-bNSpe) 6 -NH 2 (HF965A) was synthesized as previously described and dissolved in PBS before use in the cell assay [22] . All peptides were dissolved in DMSO to a concentration of 10 mM and stored at 280°C until use. Further dilutions were made in KRG [Krebs-Ringer phosphate buffer, supplemented with glucose (10 mM), Ca
2+
(1 mM), and Mg 2+ (1.5 mM)] at pH 7.3. The PAFR antagonist WEB-2086 (WEB) was from Tocris Bioscience (Bristol, United Kingdom) and Fura-2 was from Thermo Fisher Scientific (Waltham, MA, USA). The Gaq inhibitor FR900359 was isolated from the plant Ardisia crenata, as previously described [16] , whereas YM-254890 was purchased from Wako Chemicals (Neuss, Germany).
Isolation of human monocytes and neutrophils
Human peripheral blood neutrophils were isolated from buffy coats from healthy blood donors using dextran sedimentation and Ficoll-Paque gradient centrifugation as described by Bøyum et al. [23] . The remaining erythrocytes were disrupted by hypotonic lysis, the neutrophils were washed twice, resuspended in KRG, and stored on melting ice until use. This isolation procedure permits cells to be purified with minimal granule mobilization.
Human peripheral blood monocytes were isolated by centrifugation through a Ficoll-Hypaque gradient followed by Percoll gradient centrifugation as described [24] .
Determination of NADPH-oxidase activity
The NADPH-oxidase activity was determined using isoluminol-ECL [25, 26] measured in a six-channel Biolumat LB 9505 (Berthold Technologies, Bad Wildbad, Germany), using disposable, 4-ml, polypropylene tubes with a 900-ml reaction mixture containing 10 5 neutrophils or monocytes, isoluminol (2 3 emission was recorded continuously. Receptor-desensitized cells were defined as naïve (nondesensitized) cells that had first been stimulated with a receptorspecific agonist at 37°C and returned to baseline after the resulting release of superoxide, before a second stimulation. When reactivation experiments were performed with antagonists, the antagonists were added to the reaction mixtures 1 min before the second stimulation. For studies with signaling inhibitors, cells were incubated with inhibitors at 37°C before agonist addition. Control cells received no treatment but were incubated at the same basal condition as stimulated cells. To achieve FPR2-desensitized neutrophils without activation, neutrophils (10 5 /ml) were incubated at 15°C for 10 min with the FPR2-specific agonist F2Pal 10 to allow ligand binding-induced FPR2 desensitization to occur [27] ; after which, the cells were transferred to 37°C, and the incubation was continued for another 10 min. Subsequent FPR2 reactivation was trigged by addition of PAF, and the O 2 2 production was measured over time. Receptorspecific antagonists (WEB for the PAFR, 1 mM; PBP 10 for FPR2, 1 mM) or the Gaq inhibitor FR900359 (100 nM), was added 1 min before PAF.
Calcium mobilization
Neutrophils at a density of 5 3 10 7 cells/ml in KRG containing 0.1% BSA were loaded with 5 mM Fura-2-AM for 30 min in the dark at room temperature. The cells were then diluted to twice the original volume with RPMI-1640 culture medium without phenol red (GE Healthcare) and centrifuged. Finally, the cells were washed once with KRG and resuspended in the same buffer at a density of 2 3 10 7 /ml. Calcium measurements were carried out in a PerkinElmer (Waltham, MA, USA) fluorescence spectrophotometer (LC50), with excitation wavelengths of 340 and 380 nm, an emission wavelength of 509 nm, and slit widths of 5 and 10 nm, respectively. The transient rise in intracellular calcium is presented as the ratio of fluorescence intensities (340 nm:380 nm) detected.
Data analysis
Data analysis was performed in Graph Pad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). Student's t test and 1-way ANOVA, followed by Tukey's multiple comparisons test, were used for statistical analysis. *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001.
RESULTS
The neutrophil response induced by PAF is inhibited by a Gaq-specific inhibitor, whereas no such inhibition is seen when the FPR2-specific pepducin F2Pal 10 is used to activate the cells Hallmarks of neutrophil stimulation with a large number of GPCRselective agonists are the induction of the PLC-PIP 2 -IP 3 intracellular signaling pathways leading to an increase in cytosolic Ca 2+ [1] and the assembly of the O 2
2
-producing NADPH-oxidase enzyme system [3] . PAFRs and FPRs are GPCRs abundantly expressed by neutrophils, and, in accordance with the general signaling scheme, both PAF-and the FPR2-specific pepducin 
The transient rise in [Ca
2+
] i was not substantially changed by adding EGTA before activation with either PAF or F2Pal 10 , suggesting a release of Ca 2+ from intracellular stores as the initial source for the increased cytosolic concentration (Fig. 1B) . In agreement with the described receptor specificities for PAF and F2Pal 10 , the PAFR-specific antagonist WEB completely abolished the responses induced by PAF in both assay systems, and the FPR2-specific antagonist PBP 10 blocked the responses induced by F2Pal 10 . In addition, WEB was without any effects on the F2Pal 10 -induced responses, and likewise, PBP 10 had no effect on the PAFinduced responses (Figs. 1A and 2A).
The cyclic depsipeptide FR900359, which has been shown to be a specific inhibitor of Gaq-containing G proteins, was introduced to examine the involvement of Gaq in PAF-and The degree of inhibition of the PAF-induced responses was dependent on the concentration of FR900359 (shown for the oxidase activity in Fig. 2C ), and taken together, these data (summarized in Fig. 2D ) show that 1) the PAFR and FPR2 antagonists selectively inhibit the PAF and F2Pal 10 responses, respectively; and 2) the downstream signals generated by the occupied PAFR are transduced by a G protein belonging to the Gaq subclass, whereas 3) the Gaq subclass is not involved in signaling downstream of the agonist-occupied FPR2.
A very similar inhibition profile was obtained when the depsipeptide FR900359 was replaced by YM-254890, in which two CH 3 groups in FR900359 are replaced by a CH(CH 3 ) 2 group and a CH 2 CH 3 group, respectively [15, 16] . The YM-254890 compound dose-dependently inhibited the PAF-induced superoxide release but was without effect on the F2Pal 10 -induced response in concentrations up to 1 mM (data not shown).
It has long been established that neutrophil chemotactic receptors (including FPRs and PAFRs) constitute a receptors class that are all coupled to a pertussis toxin-sensitive G protein [28] . We confirmed that the responses triggered through both FPR2 and PAFRs were sensitive to pertussis toxin ( [29] ; Fig. 2E ). The cells treated with pertussis toxin for 2 h were, thus, nonresponding to PAF and F2Pal 10 but fully responsive to PMA (a reactive oxygen species inducer that signals independent of a G protein; Fig. 2E ).
The PAF-induced reactivation of desensitized FPR2 is inhibited by the cyclic depsipeptide Gaq inhibitors
The NADPH oxidase in naive neutrophils is activated by the agonist-occupied PAFR, but the amount of superoxide release is substantially increased when PAF is added to the neutrophils preactivated/desensitized with F2Pal 10 [18] . In agreement with our earlier work, the PAF-induced response was 2-to 3-fold augmented in desensitized neutrophils compared with naive cells (Fig. 3A) . The primed PAF response was inhibited not only by the PAFR-specific antagonist (WEB), but also, and more important, was inhibited by the FPR2-specific antagonist PBP 10 when added just before PAF stimulation (Fig. 3B ). This shows that the primed PAF response in F2Pal 10 -desensitized cells involves crosstalk between the two receptors, leading to reactivation of the desensitized FPR2. As shown (Figs. 1 and  2A) , the response induced in naive neutrophils activated with PAF, but not with FPR2, agonists relies on signals generated by a Gaq-containing G protein. We next examined whether the crosstalk signals leading to reactivation of FPR2 relies on Gaq.
The crosstalk response induced by PAF resulting in reactivation of FPRs (as determined by its sensitivity to an FPR antagonist) was almost completely abolished by FR900359 (Fig. 3C) . The Gaq inhibitor could be added to the cells before desensitization or just before the addition of PAF, and in both situations, the response was inhibited to the same degree (data not shown).
The PAF response induced in F2Pal 10 -desensitized cells in the presence of PBP 10 was significantly less than the PAF response induced in naive (nondesensitized) neutrophils (Fig. 3D) , suggesting a complex hierarchy between the two receptors. The FPR2-independent signaling capacity by PAFR is obviously reduced in desensitized neutrophils, and, based on the data showing that PBP 10 had no effect on PAF-induced responses in naïve neutrophils, it is likely that the two processes work in parallel, i.e., the occupied PAFRs generate signals that trigger a reactivation of desensitized FPR2, and the activated FPR2, in turn, triggers a heterologous receptor desensitization process, leading to inhibition of the direct oxidase-activating capacity of PAFRs. The FPR2 antagonist PBP 10 was also without effect on the PAF-induced rise in intracellular Ca 2+ in naïve cells, but PBP 10 partly inhibited the PAF-induced transient rise in Ca 2+ in FPR2-desensitized neutrophils (data not shown).
The response induced by PMA in FPR2-desensitized neutrophils was not affected by the FPR2 inhibitor PBP 10 (Fig. 3E) , whereas the primed PAF response was inhibited not only by this FPR2 inhibitor but also by a peptide and a lipopeptoid antagonist (Fig. 3E) . It is clear that FPR2 reactivation can only be obtained with FPR2-desensitized cells (and that means, by definition, that the cells are unresponsive to FPR2 agonists [11] ), but that does not mean that the initial burst of activation is required. This is illustrated by the fact that the PAF response induced in FPR2-desensitized neutrophils was also strongly inhibited by PBP 10 when a low-temperature (15°C) desensitization protocol was used [27] ; through which, FPR2 desensitization was achieved without any activation of the downstream signaling cascade (Fig. 3F ).
Receptor reactivation of neutrophils desensitized with the Staphylococcus aureus-derived formylated peptide PSMa2 1-16 is dependent on the Gaq signaling pathway
To further elucidate the PAFR-mediated receptor crosstalk with FPRs, we introduced community-associated, methicillin-resistant S. aureus-derived, formylated peptide PSMa2 1-16 , a dual agonist that activates both FPR2 and the closely related FPR1 but with a preference for FPR2 [21, 30] . The same type of receptor crosstalk-dependent priming of the PAF response was obtained when F2Pal 10 was replaced by PSMa2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (Fig. 4A) , and in addition, that response was inhibited by the Gaq inhibitor FR900359 (Fig. 4B and D) . In accordance with the dual receptor agonism of PSMa2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , both FPR1 and FPR2 are involved in the 2+ was measured in Fura-2-labeled neutrophils. Cells were preincubated at 37°C for 10 min without or with receptor specific antagonists (WEB = inhibitor for the PAFR, 1 mM; PBP 10 = inhibitor for FPR2, 1 mM) and the Gaq inhibitor FR900359 (100 nM), respectively, as indicated. PAF (1 nM; upper part) or F2Pal 10 (100 nM; lower part) was added at times indicated by the arrows, and the cytosolic Ca crosstalk. In line with that, only partial inhibition of the PAFinduced crosstalk response was induced by the FPR2 antagonist PBP 10 , whereas no inhibition was achieved by the FPR1-specific antagonist cyclosporine H alone (Fig. 4C and D) . The combined effect of PBP 10 and the FPR1 antagonist cyclosporine H was needed to obtain full inhibition ( Fig. 4C and D) . No reactivation was induced when the order of the agonists was reversed, that is, desensitized PAFRs are not reactivated by FPR agonists [11] .
The receptor crosstalk was also evident in monocytes, and the inhibition profile was the same in the 2 cell types for both the FPR2-specific F2Pal 10 and the dual agonist PSMa2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] (shown with PSMa2 1-16 -desensitized monocytes activated by PAF in Fig. 4E and F) . The response induced by PAF was partly inhibited by PBP 10 and fully inhibited in the presence of both PBP 10 and cyclosporine H (Fig. 4E) , and the response was abolished by FR900359 (Fig. 4F ). FR900359 could also be replaced by the other Gaq inhibitor, YM-254890, with the same inhibitory effect (data not shown). Taken together, the data presented show that the response induced by PAF in FPRdesensitized neutrophils/monocytes, rely on both PAFRs and FPRs, and the unidirectional receptor crosstalk necessarily involves intracellular signals generated downstream of a Gaqcontaining G protein.
DISCUSSION
We show that FPR2-desensitized neutrophils display a primed response when activated by PAF, and the downstream signals generated during the receptor crosstalk were redirected to depend primarily on the FPR2 signaling pathway for activation of the NADPH oxidase. We also show that the downstream sensitivity of PAFR signaling to Gaq inhibition also comprises reactivation of the desensitized FPR2, a receptor normally insensitive to Gaq inhibitors. The PAFR has been shown to couple to both Gaq and pertussis toxin-sensitive Gai, depending on the specific cell type in which the receptor is expressed in "model settings," such as in the rat basophilic leukemia cell line (RBL-2H3) [31] , neurohybrid NCB-20 cells [32] , and Xenopus oocytes [33] . In human primary neutrophils, PAFR seems to preferentially couple with Gaq for signaling and cellular activation. This conclusion is drawn from our results obtained with the recently identified Gaq small-molecule inhibitors that clearly show that the PAFR-induced intracellular increase in Ca 2+ and O 2 2 release is mediated exclusively through Gaq signaling in neutrophils. Our data showing that the activated PAFR couples to Gaq, rather than to Gai, agree with previous reports in platelets and in COS cells overexpressing the PAFR [34, 35] . The homology of different classes of G proteins is relative high and most GPCRs can couple to .1 subtype [36] , and it could, therefore, be possible (but unlikely) that other neutrophil, PAFRregulated functions are meditated through other Ga subtypes. However, it is clear that receptors usually "prefer" one Ga subtype, and other subtypes are used for signaling only in the absence of the primary G protein choice. Our data showing a complete lack of inhibition by the Gaq inhibitors FR90035 and YM-254890 on FPRs are in agreement with the generally accepted signaling dogma [1] , stating that these receptors signal exclusively through pertussis toxin-sensitive Gai-proteins and do not couple to Gaq. The transient increase in Ca 2+ was not substantially changed when extracellular Ca 2+ was chelated, suggesting that the primary source is an IP 3 -triggered ion release from intracellular storage organelles when the initiating signal is generated both by the PAFR and by FPR2. It is known that the hydrolysis of PIP 2 to generate IP 3 is mediated by the Ga subunits of the Gaq subclass, but this signaling pathway may also be triggered by bg subunits of Gai-containing G proteins [37] . The lack of effect from FR90035 and YM-254890 on the response induced by FPRs also confirms the selectively of the Gaq inhibitor shown by other groups [16] . The selectivity of these inhibitors creates a possibility for dissecting Gaq and Gai signaling differences/similarities between different GPCRs in neutrophils. Functions mediated through activation of neutrophil-chemoattractant receptors are abolished in pertussis toxin-treated neutrophils (this study and [28, 29] ), with the logical conclusion that this group of receptors, which include the PAFR, is a homogenous receptor class that all signal through a Gai-containing G protein. The difference in sensitivity to Gaq inhibitors between FPRs and PAFRs show, however, that these receptors have different preferences for coupling to G protein subclasses. One possible explanation to the inhibitory effect of pertussis toxin on the PAF-induced response in neutrophils could be that the 2-h-long incubation time needed to obtain inhibition with the toxin induced off-target effects that affect GPCR min). (B). Neutrophils (10 5 /ml) were preincubated at 37°C for 5 min without or with the Gaq-inhibitor FR900359 (100 nM). The cells were then activated through the addition of the FPR2-agonist WKYMVM (100 nM) or the FPR1-agonist fMIFL (1 nM, inset), as indicated by the arrows, and the O 2 
(E).
Neutrophils were pretreated with pertussis toxin (PTX, 500 ng/ml final concentration) at 37°C for different periods of time, and the neutrophil superoxide production in response to F2Pal 10 (black bars) or PAF (gray bars) was determined. The response induced by PMA (50 nM, a non-G proteindependent stimulus; white bars) was included to ensure proper cell function after the 120 min incubation period. The peak superoxide anion-response values were determined, and the results are given as the ratio between the responses of cells incubated with and without PTX, respectively. Abscissa, time of incubation with pertussis toxin; ordinate, superoxide release presented as the ratio of +PTX:2PTX (means 6 SEM; n = 3). **P # 0.01; ***P # 0.001.
signaling in neutrophils, effects that are not picked up by the PMA control. Future identification of small-molecule inhibitors that are selective for Gai should help dissect Gai use by the different neutrophil GPCRs.
Signaling by FPR2, as well as by the closely related FPR1, is terminated fairly rapidly, and the receptors become homologously desensitized. We have previously shown that desensitized FPR1 and FPR2 can be reactivated by the agonist binding to the production induced in F2Pal 10 -desensitized neutrophils is inhibited by WEB (PAFR antagonist, 1 mM, dashed line) and PBP 10 (FPR2 antagonist, 1 mM, dotted line). Desensitized neutrophils were achieved through activation with the FPR2-specific agonists F2Pal 10 (500 nM; the response induced is not included in the figure) , and after termination of the F2Pal 10 -induced response, the inhibitors were added (time points for addition indicated by the arrow to the left), and the cells were subsequently reactivated with PAF (100 nM; added as indicated by the arrow to the right). Abscissa, time of study (min); ordinate, O 2 2 production given in arbitrary units (Mcpm). Inset: Inhibition of the PAF (100 nM)-induced reactivation in F2Pal 10 -desensitized neutrophils by the receptor-specific antagonists PBP 10 , (1 mM) and WEB (1 mM). The results are given as remaining activity in the presence of the inhibitor expressed as a percentage of the activity (peak value) induced by PAF in the absence of any inhibitor (means 6 SD; n = 3). ****P # 0.0001. (C). The PAF-induced O 2 2 production induced in F2Pal 10 -desensitized neutrophils is inhibited by the Gaq-inhibitor FR900359. Desensitized neutrophils were achieved through activation with the FPR2-specific agonists F2Pal 10 (500 nM; the response induced is not included in the figure) and after termination of the F2Pal 10 -induced response, the inhibitor was added (time point for addition indicated by the arrow to the left, dashed line) or not added (solid line), and the cells were subsequently reactivated with PAF (100 nM; added as indicated by the arrow to the right). Abscissa, time of study (minutes); ordinate, O 2 2 production given in arbitrary units (Mcpm). Inset: Inhibition of the PAF (100 nM)-induced reactivation in F2Pal 10 -desensitized neutrophils by FR900359 (100 nM). The results are given as remaining activity in the presence of the inhibitor expressed as a percentage of the activity (peak value) induced by PAF in the absence of inhibitor (means 6 SD; n = 3). ****P # 0.0001. (D). The direct PAFR-dependent O 2 2 production is reduced in FPR2-desensitized neutrophils. Naive neutrophils were activated by PAF (100 nM), superoxide production was measured, and the activity is given as the peak value of the response (black bar; means 6 SD; n = 3); superoxide production induced by PAF (100 nM) in F2Pal 10 -desensitized neutrophils was determined in the presence of the FPR2-antagonist PBP 10 (1 mM) that was added to the cells 1 min before PAF (gray bar; means 6 SD; n = 3). *P # 0.05. (E). Inhibition by FPR2 inhibitors on PAF-and PMA-induced superoxide production measured in F2Pal 10 -desensitized neutrophils. The cells were first activated by FPR2-specific agonists F2Pal 10 (500 nM), and after termination of the F2Pal 10 -induced response, the desensitized neutrophils were subsequently activated/reactivated with PAF (100 nM) or PMA (50 nM) in the absence or presence of the FPR2 inhibitor (HF965A, 500 nM, gray bar, or WRWWWW, 1 mM, white bar for PAF; PBP 10 , 1 mM for PMA, black bar). The results are given as remaining activity in the presence of the inhibitor expressed as a percentage of the activity (peak value) induced by PAF/PMA in the absence of any inhibitor (means 6 SD; n = 3). **P # 0.005 (F). The PAF-induced O 2 2 production induced in F2Pal 10 -desensitized neutrophils is inhibited by the Gaq-inhibitor FR900359 and when no initial burst in activity is obtained. Desensitized neutrophils were achieved through an interaction with the FPR2-specific agonists F2Pal 10 (500 nM) at 15°C. The temperature was increased to 37°C during a 10-min period; after which, FPR2-inhibitor PBP 10 was added (time point for addition indicated by an arrow, dashed line) or not (solid line), and the cells were subsequently reactivated with PAF (100 nM; added as indicated by the arrow to the right). Abscissa, time of study (min); ordinate, O 2 2 production given in arbitrary units (Mcpm).
PAFR and to P2Y 2 R, and this reactivation can only be obtained with FPR-desensitized neutrophils, and the desensitizing agonist has to be present when the reactivating agonist is added [11] . The reactivation signal is most pronounced when an "unconventional agonist," such as the FPR2 pepducin, is used to activate/desensitize the receptors, and the magnitude of the reactivation response induced is directly related to the concentration of the FPR2 agonist [18] . Pepducins are synthetic, lipidated peptides, consisting of an amino acid sequence corresponding to one of the intracellular domains of the receptor. This sequence is conjugated in the N terminus with a fatty acid. The hydrophobic moiety has been suggested as an anchor to the cell membrane to "allow" the peptide part to flip to the intracellular part and to allosterically activate or inhibit its cognate receptor, (for recent reviews see [3, 38, 39] ). F2Pal 10 is a pepducin derived from the third intracellular loop of FPR2 [18] , and in accordance with the pepducin "dogma," F2Pal 10 selectively activates FPR2 and has no effect on the closely related FPR1. However, the functional response is inhibited by a conventional antagonist, and the binding can be outcompeted by an orthosteric agonist [18] . These data put the pepducin dogma to question, at least when it comes to FPR2, and that questioning is strongly supported by data showing that FPR2 is activated by pepducins originating from P2Y 2 R and CXCR4, receptors that have no sequence similarities to FPR2 [40, 41] . Importantly, in the context of crosstalk, the PAFR-initiated crosstalk is not limited to the F2Pal 10 -desensitized receptors or the FPR2-inhibitor PBP 10 ; the inhibitor could be replaced by two other FPR2 specific/selective inhibitors, the widely used WRW 4 -peptide [42] and a recently described FPR2 peptidomimetic-inhibitor Pam-(Lys-bNSpe) 6 -NH 2 [22] , and the same results in crosstalk and sensitivity to the Gaq inhibitor are obtained when the F2Pal 10 pepducin is replaced with a conventional peptide agonist (the formylated peptide PSMa2 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] ). The receptor crosstalkreactivation mechanism is clearly dependent on Gaq, and the data presented show that the signals that initiate the crosstalkregulated reactivation are most likely downstream of that G protein subunit and are not due to a change of function because of receptor dimerization between the 2 communicating receptors. The nature of the crosstalk signal is not known, and because the effector function (the desensitized FPR target) is missing in naive neutrophils, it is not possible to determine whether the signal is generated by the PAFR only in desensitized neutrophils or in naive cells as well. The initial FPR-mediated activation step is, however, not required; FPR desensitization can be achieved without any activation of the downstream signaling cascade [27] , and the same pattern of PAF-induced reactivation of FPR2 was obtained with these cells, clearly showing the initial FPRmediated burst in activity is not a prerequisite for reactivation. The exact nature of the intracellular signaling downstream of the Gaq-protein can, at this point, only be speculated on, but the data suggest that the FPR-reactivation signal is not the same as the NADPH oxidase-activating signal generated by the PAFR. This conclusion is based on the NADPH oxidase activity induced by PAF in FPR2-desensitized cells, measured as superoxide release in the presence of an FPR2 antagonist, is largely reduced when compared with the PAF-induced activity in naive neutrophils. The FPR-reactivation signal is most probably not the same as that leading to direct activation by FPR agonists in naive cells, based on calyculin A greatly reducing the crosstalk-dependent reactivation, whereas NADPH-oxidase activity induced by the FPR agonist in naive neutrophils is increased by the phosphatase inhibitor [18] . We have attempted to elucidate the molecular mechanisms underlying receptor desensitization and reactivation per se, but a complete understanding of the crosstalk mechanism is hindered by the general lack of knowledge regarding the termination of signaling by neutrophil GPCRs. It is well established that termination of signaling through GPCRs is typically achieved through b-arrestin binding, a process suggested to mediate both homologous desensitization and signaling termination [43] . The formation of a GPCR-arrestin complex sterically blocks binding of the G protein, but in neutrophils, the actin cytoskeleton, rather than b-arrestin, seems to have an important role in the physical separation of agonist-occupied FPRs from the signaling G protein, and such physical separation eventually terminates the signaling from the occupied FPRs [44] [45] [46] . The model for how the neutrophil GPCRs become desensitized is very similar to the b-arrestin model, except for the role of actin to separate the receptor from the G protein in the plane of the plasma membrane. A possible activation mechanism could thus involve signals generated by the agonist-occupied PAFR that affect the cytoskeleton and allow the desensitized FPRs to be transferred to a signaling state.
Taken together, the data presented provide direct evidence for receptor crosstalk between the PAFR and FPRs in both neutrophils and monocytes, resulting in reactivation of desensitized FPRs, and crosstalk-reactivation signals are generated by the Gaq-containing G protein downstream of the PAFR. Our data show that Gaq inhibitors have no direct effects on FPR-induced responses in naive neutrophils, whereas the response is inhibited when the desensitized receptors are reactivated. The receptor-crosstalk mechanism is thus initiated by the PAFR, and the signals generated by that receptor in FPR-desensitized neutrophils were both inhibited (direct activation of the oxidase) and redirected to reactivate the desensitized receptors. The Gaq dependency of the PAFR comprised FPR2, and the crosstalk signals that reactivate this receptor are generated downstream of Gaq. The activation signals through which the Gaq-coupled PAF receptor activates the Gaicoupled FPRs represent a novel pathway by which G proteincoupled receptors can be regulated and signaling can be turned on and off. It is clear that G protein activation, mediated by a single GPCR, can trigger the production of many messenger molecules that secondarily regulate many different cell functions. We now add to that the ability of a GPCR to exploit the signaling capacity of another GPCR, a process brought about through a receptor-crosstalk reactivation mechanism. AUTHORSHIP C.D. and H.F. designed the study, analyzed the data, and wrote the manuscript. G.M.K. and E.K. isolated the Gaq inhibitor FR900359. A.H., A.D.R., M.G., and Z.R. performed and analyzed the experiments and provided scientific suggestions. All authors approved the final version of the manuscript.
